NCT04022005View on ClinicalTrials.gov

Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

June 19, 2019

Primary Completion Date

November 16, 2022

Study Completion Date

March 11, 2023

Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
DRUG

Chidamide, Rituximab, Gemcitabine,Oxaliplatin

"All patients enrolled in the study will accept Chidamide + R-GemOx (Rituximab, Gemcitabine and Oxaliplatin) as their salvage chemotherapy.~Patients with CR or PR will receive chidamide maintenance therapy."

Trial Locations (1)

51000

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT04022005 - Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL | Biotech Hunter | Biotech Hunter